News Gilead presses go on first Nurix protein degrader drug Opt-in for IRAK4 drug comes after a Kymera/Sanofi candidate showed early activity in trials.
News Double blow for Sangamo as Novartis, Biogen exit deals The two deals for gene-modifying candidates were worth up to $3.1 billion including milestones.
News Mersana stung by FDA hold on STING drug Death in ph1 trial casts a pall over GSK-backed project, licensed for $100m upfront last year.
News Lilly adds to non-opioid pain pipeline with Confo deal Deal covers an AT2R inhibitor, a class that has been plagued by safety and efficacy issues.
News Morphic loses second partner as J&J exits integrin alliance Morphic Therapeutic has lost Johnson & Johnson's Janssen Pharma as a partner, following the termination of an alliance to develop drugs targeting integrins first agreed in 2019.
News Digital health investors getting choosier as sector matures Despite the well-documented retreat from record levels of funding for digital health ven
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
